AzTrials
AzTrials

Vomiting, PostoperativePhase 3NCT04613726

The Effect of Intravenous Granisetron and Ondansetron in Patients Undergoing Cesarean Section

A Phase 3 study testing ondansetron, Granisetron and Saline in people with Vomiting, Postoperative and Postoperative Complications, run by Ataturk University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study compared the effects of prophylactic intravenous (IV) infusion of ondansetron and granisetron before the spinal anesthesia on hemodynamic parameters in patients undergoing elective cesarean section. Read more about this study

Who is it for?
Ages 18 to 45 years, women onlyHealthy volunteers can take part
What is being tested?
ondansetron, Granisetron and Saline
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
1 siteTurkey (Türkiye)
Study dates
3 Dec 2018to 1 Jan 2020
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • aged between 18-45 years
  • uncomplicated term pregnancy
  • ASA (American society of anesthesiologist) I or II
  • undergoing elective cesarean section with combined spinal-epidural anesthesia

Who cannot join

  • psychiatric diseases
  • preeclampsia
  • pregnancy-induced hypertension
  • chronic hypertension
  • diabetes
  • multiple pregnancies
Show all 9Show fewer
  • fetal anomaly
  • allergy to study drugs
  • receiving selective serotonin reuptake inhibitors

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Mehmet AKSOY

    Erzurum, string:Turkey, 25240

Other trials in Turkey (Türkiye)

About this study

Official title: Intravenous Granisetron Provides Less Ephedrine Requirement Than Ondansetron in Patients Undergoing Cesarean Section With Spinal Anesthesia: A Randomised Placebo-controlled Trial

This study compared the effects of prophylactic intravenous (IV) infusion of ondansetron and granisetron before the spinal anesthesia on hemodynamic parameters in patients undergoing elective cesarean section.

Read the detailed description

A total of 120 parturients who agreed to participate in the study with uncomplicated term pregnancy, aged between 18-45 years, American society of anesthesiologist I or II undergoing elective cesarean section with combined spinal-epidural anesthesia (CSEA) were included. Participants with complicated pregnancy such as diabetes, pregnancy-induced hypertension or chronic hypertension, fetal anomaly, a history of allergy to study drugs, psychiatric diseases, coagulation abnormalities and mul¬tiple pregnancies were excluded from the study. Also, patients receiving selective serotonin reuptake inhibitors were excluded.

A day before surgery, detailed anamnesis was obtained from the patients and a general systemic examination was performed. Also, patients were informed about the study protocol and written informed consent was obtained. The patients were informed that they should be fasting for 8 hours before surgery. On the day of operation, peripheral intravenous (IV) access was provided using a 16-gauge/18-gauge cannula.

After all patients received 500 ml of Ringer Lactate as preload, they were transferred to the operating room. None of the patients received premedication. Before the anesthesia procedure; patients' age, weight, height, ASA physical status, baseline systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were recorded. The study medications were prepared by an anesthesia resident who was not involved in the study. Three groups (n=40, for each group) were formed by randomization using a computer-generated table of random numbers. The anesthesiologist in charge, and the patient and investigators were blinded to the group allocation.

Five minutes before the CSEA procedure, Group I received IV 8 mg ondansetron diluted in 10 ml of normal saline, Group II received IV 3 mg granisetron diluted in 10 ml of normal saline, and Group III received IV 10 ml normal saline. Subsequently, combined spinal-epidural anesthesia (CSEA) in the sitting position was performed in all patients. Following skin sterilization and local anesthetic infiltration (2% lidocaine), 18 gauge Tuohy needle (Set for CSEA, Braun®, Melsungen, Germany) was advanced through the midline L2-3 or L3-4 intervertebral spaces with loss of resistance technique. A 27-gauge pencil point needle was inserted intrathecally, using the needle-through-needle technique. After free cerebrospinal fluid flow was observed, 1.8 ml 0.5% isobaric bupivacaine (9 mg) and 15 µg fentanyl was administered over 30 seconds. Then, the spinal needle was removed and epidural catheter was advanced 3 to 5 cm into the epidural space. The catheter was secured in place after it was checked with negative pressure. At the end of the anesthesia procedure, patients were placed in the supine position for operation and the operating table was tilted 20° to the left. Sensory block level was evaluated via pinprick test and when the sensory block reached at the upper level of T6 dermatome, surgery was initiated. If sensory block were not observed within the first 20 min following the spinal injection, spinal anesthesia was considered as failed. In this instance, additional 5 ml solution of 2% lidocaine was injected via the epidural catheter until a T6 level of the sensory block was provided and these patients were excluded from the study. Motor block level was evaluated with Modified Bromage scale (scale 0 = The patient is able to move hip, knee, ankle, and toes.; scale 1 = The patient is able to the full flexion of foot and knee, she is unable to hip flexion; scale 2 = The patient is able to the full flexion of foot, she is unable to knee and hip flexion; scale 3 = Total motor block is available). General anaesthesia protocol was planned in case of three unsuccessful attempts to reach to intrathecal space. Oxygen was delivered during surgery. Intravenous ephedrine (6 mg) was planned to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) and intra¬venous atropine (1 mg) was planned in case of bradycardia (the heart rate < 45 beats/minute) during surgery. In case of nausea and vomiting, intravenous metoclopramide (10 mg) was administered. Following drug administration to the intrathecal space, intraoperative hemodynamic changes were recorded every 2 min for 20 min and then every five minutes until the end of the operation by an anesthetist who was blinded to the group allocation. The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications such as pruritus and nausea-vomiting and the number of patients requiring epidural medication, ephedrine and atropine during surgery were recorded. Neonatal Apgar scores at 1 and 5 min after delivery and umbilical artery blood gas values were recorded.

After operation, patients were evaluated in the recovery room for 120 min. Visual analogue scale (VAS, 0 cm= no pain, 10 cm= worst pain) scores for pain severity, anesthesia-related side effects (e.g., nausea, vomiting and headache), sensory block time (from the spinal injection to the recovery of T10 dermatome), and the time requiring supplemental analgesics was recorded by an independent observer blinded to the group assignment at 30 min and 1st and 2nd hours post-operatively. In the case of VAS > 3 in a patient, 10 ml solution of 0.1% bupivacaine was given via the epidural catheter. Patients were transferred to the ward, following the motor block had regressed to the T10 level.

The primary end point of the study was the ephedrine requirement during surgery. The minimum sample size required for this study was calculated using the Russ Lenth's Power and sample size calculation application. Thirty-five patients in each group were needed to demonstrate a mean difference in the requirement of 10 mg ephedrine among groups with a power of 90% and alpha 5%. However, a sample size was determined as 40 in each group, considering potential dropouts.

Data were expressed as mean values ± standard deviation (SD) or number and percentage values. Comparisons were performed using the ANOVA test. The percentage values were compared using chi-square, P<0.05 was considered significant statistically.

Being tested
ondansetron, Granisetron, Saline
Keywords
cesarean section, granisetron, ondansetron, spinal anesthesia, blood pressure, pre-treatment
Medical subject headings
Postoperative Nausea and Vomiting, Postoperative Complications, Hypotension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ondansetronDrug

    group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline

  • GranisetronDrug

    Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline

  • SalineDrug

    Control group consisted of patients receiving IV 10 ml normal saline

Study groups in NCT04613726
Study groupRoleWhat they receive
IV 10 ml normal salinePlacebo comparatorControl group consisted of patients receiving IV 10 ml normal saline.
Receives: Drug: Saline
IV 8 mg ondansetron in 10 ml of normal salineActive comparatorThis group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline,
Receives: Drug: ondansetron
IV 3 mg granisetron in 10 ml of normal salineActive comparatorThis group consisted of receiving IV 3 mg granisetron diluted in 10 ml of normal saline.
Receives: Drug: Granisetron

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ephedrine requirement

    The change in ephedrine requirement during surgery (mg).

    Measured: Every two minutes during surgery.

Secondary outcomes (4)
  1. atropine requirement

    The change in atropine requirement during surgery (mg).

    Measured: every two minutes during surgery

  2. analgesic requirement

    The change in analgesic requirement during surgery and postoperative 24 hours(mg)

    Measured: every five minutes during surgery and postoperative 24 hours

  3. blood pressure values

    The change in systolic and diastolic blood pressure values (mmHg).

    Measured: every two minutes during surgery

  4. heart rate values

    The change in heart rate values (bpm).

    Measured: every two minutes during surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2020
  2. Study start3 Dec 2018
  3. Primary completion12 Dec 2019
  4. Study completion1 Jan 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Comparator / control treatment Control group consisted of patients receiving IV 10 ml normal saline. A comparator group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline, Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04613726
Sponsor's protocol ID
B.30.2.ATA.0.01.00/166
Status last verified
Nov 2020
First submitted
23 Oct 2020
Last updated
3 Nov 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing ondansetron, Granisetron and Saline in people with Vomiting, Postoperative and Postoperative Complications, run by Ataturk University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ephedrine requirement (time frame: Every two minutes during surgery.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in